Prab: CSV import

2025-03-17T13:59:35Z

CSV import

← Older revision		Revision as of 13:59, 17 March 2025
Line 30:		Line 30:
	{{pharmacology-stub}}		{{pharmacology-stub}}
	{{No image}}		{{No image}}
			__NOINDEX__

Prab: CSV import

2025-02-10T19:07:25Z

CSV import

← Older revision		Revision as of 19:07, 10 February 2025
Line 29:		Line 29:

	{{pharmacology-stub}}		{{pharmacology-stub}}
			{{No image}}

Prab: CSV import

2024-03-08T18:35:56Z

CSV import

New page

'''Heterologous desensitisation''' is a biological process that occurs when a cell becomes less responsive to stimulation by a specific agonist due to prior exposure to a different agonist. This phenomenon is a form of [[Adaptive immunity|adaptive immune response]] and is a key component of the body's ability to regulate its responses to various stimuli.

== Mechanism ==

The mechanism of heterologous desensitisation involves the down-regulation of [[G protein-coupled receptor|G protein-coupled receptors]] (GPCRs) on the cell surface. When a cell is exposed to an agonist, the GPCRs bind to the agonist and initiate a series of intracellular events that lead to the cell's response. However, if the cell is subsequently exposed to a different agonist, the GPCRs may become less responsive or even unresponsive to the original agonist. This is due to a process called [[Receptor desensitisation|receptor desensitisation]], in which the receptors are phosphorylated and internalised, reducing their availability on the cell surface.

== Role in Disease ==

Heterologous desensitisation has been implicated in a number of diseases, including [[Asthma|asthma]], [[Chronic obstructive pulmonary disease|COPD]], and [[Heart failure|heart failure]]. In these conditions, the desensitisation of GPCRs can lead to a reduced response to medications that target these receptors, resulting in decreased efficacy of treatment.

== Research and Future Directions ==

Research into heterologous desensitisation is ongoing, with a focus on understanding the precise mechanisms involved and how they can be manipulated for therapeutic benefit. Potential areas of interest include the development of drugs that can prevent or reverse receptor desensitisation, and the use of genetic engineering to modify the expression of GPCRs in disease states.

== See Also ==

* [[Homologous desensitisation]]
* [[G protein-coupled receptor]]
* [[Receptor desensitisation]]
* [[Adaptive immunity]]

== References ==

<references />

[[Category:Cell biology]]
[[Category:Immunology]]
[[Category:Pharmacology]]

{{pharmacology-stub}}

Heterologous desensitisation - Revision history

Prab: CSV import

Prab: CSV import

Prab: CSV import